Publication Name	World Journal of Clinical Cases
Manuscript ID	88795
Country	Japan

Received	2023-10-11 05:39
Peer-Review Started	2023-10-11 05:41
To Make the First Decision
Return for Revision	2023-10-24 06:34
Revised	2023-11-04 11:27
Second Decision	2023-11-21 03:53
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-11-30 05:03
Articles in Press	2023-11-30 05:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-12-06 16:01
Publish the Manuscript Online	2023-12-14 06:01

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Hiroyasu Yamashiro and Nao Morii
Funding Agency and Grant Number
Corresponding Author	Hiroyasu Yamashiro, MD, PhD, Director, Director, Department of Breast Surgery, Tenri Hospital, No. 200 Mishima-cho, Tenri 632-8552, Nara, Japan. yamashiro.bcs@gmail.com
Key Words	Breast cancer; HER2 negative; Brain metastasis; Abemaciclib; Drug-induced interstitial lung damage; Case report
Core Tip	In this case report, we address the critical issue of limited therapeutic options for HER2-negative breast cancer patients with brain metastases. We present a case of a woman with estrogen receptor-positive, HER2-negative breast cancer who initially exhibited an encouraging response to abemaciclib and letrozole therapy for brain metastases. However, this treatment had to be discontinued due to drug-induced lung damage. This study reports the challenges of achieving a balance between efficacy and adverse events in managing brain metastases and highlights the need for alternative treatment strategies in this patient population.
Publish Date	2023-12-14 06:01
Citation	Yamashiro H, Morii N. Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report. World J Clin Cases 2023; 11(35): 8425-8430
URL	https://www.wjgnet.com/2307-8960/full/v11/i35/8425.htm
DOI	https://dx.doi.org/10.12998/wjcc.v11.i35.8425

Full Article (PDF)	WJCC-11-8425-with-cover.pdf
Full Article (Word)	WJCC-11-8425.docx
CARE Checklist–2016	88795-CARE Checklist (2016).pdf
Manuscript File	88795_Auto_Edited-JLW.docx
Answering Reviewers	88795-Answering reviewers.pdf
Audio Core Tip	88795-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	88795-Conflict-of-interest statement.pdf
Copyright License Agreement	88795-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	88795-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	88795-Language certificate.pdf
Peer-review Report	88795-Peer-review(s).pdf
Scientific Misconduct Check	88795-Bing-Qu XL-2.jpg
Scientific Editor Work List	88795-Scientific editor work list.pdf
CrossCheck Report	88795-CrossCheck report.pdf